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ABSTRACT
Background and Purpose: Polymorphisms and serum levels of Matrix 
Metalloproteinases (MMP) and Tissue Inhibitor of Metalloproteinases (TIMP) have 
been studied with regard to atheromatous plaques and ischemic stroke, while no 
studies of DNA methylation (DNAm) patterns of MMP or TIMP have been performed 
to that end. Here, we evaluate DNAm levels of the MMP and TIMP gene families in 
human carotid plaques and blood samples of atherothrombotic stroke patients.
Methods: We profiled the DNAm status of stable and ulcerated atherosclerotic 
plaques obtained as pair sets from three patients who underwent carotid 
endarterectomy surgery. We selected 415 CpG sites, mapping into MMPs and TIMPs 
genes for further study. Secondly, the statistically associated CpG sites were analyzed 
in blood samples from two separate atherothrombotic stroke cohorts (total sample 
size = 307), ischemic stroke-cohort 1 (ISC-1): 37 atherothrombotic patients and 6 
controls, ischemic stroke-cohort 2 (ISC-2): 80 atherothrombotic patients and 184 
controls. DNAm levels from plaque tissue and blood samples were evaluated using 
a high-density microarray Infinium, HumanMethylation450 BeadChip and Infinium 
MethylationEPIC BeadChip.
Results: Three CpG sites were statistically significantly associated with unstable 
plaque portions; cg02969624, q-value = 0.035 (TIMP2), and cg04316754, q-value = 
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INTRODUCTION
Arteriosclerosis is the underlying pathology in most 
cases of cardiovascular disease (CVD), including ischemic 
stroke (IS), contributing to major mortality in Western 
countries. Atherosclerosis is a process that involves a 
complex interaction between different factors and cell 
types, including cells of the vessel wall and immune 
system. During their formation, atherosclerotic lesions 
undergo different stages, starting from inflammatory 
endothelial activation/dysfunction and resulting in plaque 
vulnerability and rupture [1].
Matrix Metalloproteinases (MMPs) are a family 
of zinc-binding proteolytic enzymes that are known for 
their ability to cleave one or more extracellular matrix 
constituents, as well as other proteins [2]. MMPs and their 
specific inhibitors, tissue inhibitors of metalloproteinases 
(TIMPs), are involved in many processes, including 
wound healing, angiogenesis, inflammation, and blood-
brain barrier disruption [2, 3]. Uncontrolled expression of 
MMPs can result in tissue destruction and inflammation. 
MMPs and TIMPs have raised considerable interest within 
the atherosclerosis and IS research community, as they 
represent an attractive target for the use of current drugs 
and the development of novel ones, aimed at blocking 
MMP activity [4].
Some studies have observed associations between 
protein plasma levels of MMPs, TIMPs, atheromatous 
plaque instability [5, 6], stroke progression [7]. 
However, few studies have investigated the relationship 
between DNA methylation (DNAm) and atherosclerosis 
pathogenicity [8–10] and none have focused on the MMP 
and TIMP gene families. Zaina et al., observed widespread 
hypermethylation in the atherosclerotic portion of 15 
aorta samples compared to healthy counterparts [9]. 
In a different study, Zaina et al., detected small DNAm 
changes between 19 symptomatic and asymptomatic 
plaque pairs, and a drift toward hypomethylation, 
associated with increasing post-cerebrovascular event 
time [8], whereas others identified a set of CpGs that drift 
toward hypermethylation with lesion progression [10], in 
15 sample-pairs.
Here, we present a characterization of DNAm status 
of the MMP and TIMP gene families in donor-matched 
stable and ulcerated carotid artery atherosclerotic plaques 
and whole blood in atherothrombotic stroke patients and 
controls.
RESULTS
Seventy-two differentially methylated CpGs were 
observed between normal and ulcerated plaque portions 
(p-value < 0.05) (Supplementary Table 3). Sixty of them 
were hypermethylated in the ulcerated portion, and 
twelve were hypomethylated. Three CpGs passed FDR 
adjusted p-value (or q-value), two were hypermethylated: 
cg02969624, q-value = 0.036 mapping in TIMP2, and 
cg04316754, q-value = 0.037 mapping in MMP24; 
whereas cg24211657 q-value = 0.036 mapping in TIMP2 
was hypomethylated (Figure 1B) (Supplementary Table 4).
Supervised clustering of the 72 significant sites 
distinguished all atherosclerotic lesions from their donor-
matched healthy counterparts (Figure 2). Good clustering 
was also observed when using all 415 CpGs, highlighting 
the specificity of the MMPs and TIMPs in plaque 
progression discrimination (Supplementary Figure 2).
All CpGs were also interrogated in two independent 
blood sample ischemic stroke cohorts of atherothrombotic 
stroke subtype (TOAST classification), 415 CpGs in ISC-1 
and 355 CpGs in ISC-2 (Supplementary Table 3). One of the 
significantly associated CpGs identified in the initial plaque 
study was also associated with the risk of atherothrombotic 
stroke. Thus, cg04316754, MMP24, was up-methylated in 
control samples when compared to cases in both cohorts. In 
ISC-1, we found a significant association of cg04316754 
(Moldel_2 p-value = 0.025) that was also replicated in ISC-
2 (Model_1 p-value = 1.9 × 10-04) (Supplementary Table 5) 
(Figure 1A). Thus, cg02969624 and cg24211657 (TIMP2) 
were up-methylated in control samples when compared to 
cases, but their association was not statistically significant 
in either of the two ischemic cohorts.
An overall hypermethylation of MMPs and TIMPs 
genes was observed in plaque tissue samples, with a 
65.7% of CpG up-methylated in the unstable portion 
of the plaque compared to the stable counterparts 
(Supplementary Figure 3A). The same behavior was 
detected when interrogating both blood-sample cohorts, 
with a 70.85% of CpGs up-methylated in case samples 
compared to atherothrombotic stroke patients in ISC-
1 and 63.48% of the CpG up-methylated in ISC-2 
(Supplementary Figure 3A). This trend was observed 
across all gene mapping compartments, mostly in the 
gene body and gene-TSS1500, and across all CpG islands 
regions, as well as in sites mapping into enhancer regions 
(Supplementary Figure 3B–3D).
0.037 (MMP24) were hypermethylated, while cg24211657 q-value = 0.035 (TIMP2) 
was hypomethylated. Association of cg04316754 (MMP24) methylation levels with 
atherothrombotic risk was also observed in blood tissue: ISC-1 p-values = 0.03, ISC-
2 p-value = 1.9 × 10-04.
Conclusions: The results suggest different DNAm status of MMP24 between stable 
and unstable atherothrombotic carotid plaques, and between atherothrombotic stroke 
and controls in blood samples.
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DISCUSSION
The role of MMPs in atherosclerosis has been 
extensively evaluated and their activity is essential 
for many processes involved in atherosclerotic plaque 
formation, such as infiltration of inflammatory cells, 
smooth muscle cell migration and proliferation and 
angiogenesis [11]. Furthermore, matrix degradation by 
MMPs causes plaque instability and rupture leading to 
unstable angina, myocardial infarction and stroke [12]. 
Müeller et al., identified increased expression levels of 
MMP1, MMP9, MMP12, and MMP14 in vulnerable 
plaques compared to stable ones, and lower expression 
levels in MMP2 and TIMP3 vulnerable plaques [5]. In 
contrast, Sapienza et al., observed an imbalance between 
MMPs and TIMPs plasma levels in unstable carotid 
plaques [6]. A recent multiancestry genome-wide-
association meta-analysis [7] identified a locus in MMP12 
associated with atherothrombotic stroke, where the lead 
SNP was also associated with methylation and protein 
quantitative trait loci (meQTL and pQTL) [7].
In our study, unstable plaque samples had 65.7% of 
CpG up-methylated compared to their stable counterparts, 
indicating a trend to hypermethylation. These findings 
were most evident at the body and TSS1500 regions of 
the genes. Our results are in line with those of others, 
who observed a broad trend of DNA hypermethylation in 
plaque progression [8–10]. Zaina et al., observed pattern 
of genome-wide hypermethylation in atherosclerotic 
plaques, suggesting that an atherosclerosis-specific DNA 
methylation profile is established in the early stages of 
plaque evolution [9]. In a separate study, Zaina et al., 
identified small DNAm changes between symptomatic and 
asymptomatic plaques and an association with increasing 
post-cerebrovascular event time [8]. They observed a 
general hypermethylation in the plaque in early post-
cerebrovascular event time compared to asymptomatic 
plaque. In another study that analyzed donor-matched 
atherosclerotic and normal aortic samples, the authors 
observed a correlation between histological grade and 
differential methylation between plaque pairs for 1,985 
CpGs, most of which drifted toward hypermethylation 
with lesion progression [10].
MMP24 is a protease, member of the membrane-
type MMP (MT-MMP), a subfamily in the matrix 
metalloproteinases-family, characterized by having a 
transmembrane domain and being expressed at the cell 
surface. Substrates of this protease include the proteins 
cadherin-2 and MMP2. Here, we present the first reported 
association between MMP24 and atherosclerosis, although 
Figure 1: Differentially methylated levels of cg04316754 (MMP24). (A) Boxplot: differentially methylated status of cg04316754. 
X-axis indicates sample type, in each cohort. Y-axis indicates DNA methylation levels (β-values = 0–1).0 = 0% methylation status, 1 = 
100% methylation status. (B) Statistically significant differentially methylated CpG sites in plaque tissue, annotation and statistical results 
in the three cohorts.
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links with other MMPs in the MT-MMP subtype have 
been described before. For instance, MMP14, a member 
of the MT-MMP subfamily, has been implicated in acute 
myocardial infarction. Moreover, expression of MMP14 
can influence collagen content of mouse plaques, implying 
an important role for MMP14 in plaque stability [13]. 
While MMP24 was not assessed, a study reported, higher 
gene expression levels of MMP14 in vulnerable plaques 
than stable plaques, (no other member of MT-MMP 
subfamily was interrogated) [5].
Figure 2: Cluster analysis of donor-matched aortic plaque samples. Supervised clustering of 72 CpGs nominal association. 
Columns represent samples, horizontal lines represent CpGs. Notice the perfect segregation between stable and unstable plaque counterpart.
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Our results indicate a distinct methylation state of 
the CpG site cg0431675 in MMP24 between stable and 
unstable carotid plaque, which we have also detected 
associated with atherosclerotic stroke in two independent 
cohorts. A trend to hypermethylation is observed in 
unstable plaque-portion and non-stroke control samples, 
which falls into line with what has been postulated by 
others, i.e., that ruptured plaques tend to revert to a stable 
structure. Zaina et al., in their study, observed an initial 
hypermethylation in the transition from asymptomatic 
plaque to early post-cerebrovascular event time, followed 
by a reversion to initial methylation levels with increasing 
post-cerebrovascular event time, suggesting a process 
of plaque remodeling to a more stable phenotype [8]. 
Peeters W et al., proposed that ruptured plaques remodel 
to a relatively stable structure after stroke events [14]. 
They identified higher macrophage infiltration in carotid 
plaques, obtained from patients operated early after 
stroke, compared with asymptomatic patients, as well as 
significantly elevated levels of a set of proinflammatory 
cytokines and MMP8, MMP9, and MMP2 activity [14].
TIMP2, in addition to its role as metalloproteinase 
inhibitor, can directly suppress the proliferation of 
endothelial cells. TIMP2 is a rather large gene, with 
62 CpG sites of the 450k array mapping into the gene. 
Two CpG sites, in different regions of TIMP2, were 
statistically associated with plaque progression in our 
study, although this association was not observed between 
atherothrombotic stroke and control samples, either in 
statistical significance or directionally. Therefore, we 
cannot conclude much from those results, except that the 
most known activity of TIMP2 is MMP2 regulation [11]. 
It has been reported that human carotid plaque extracts 
promote platelet aggregation due to their MMP2 content, 
which can be inhibited by TIMP2, and that the ratio of 
MMP2/TIMP2 of plaques potentiating platelet aggregation 
is significantly higher than that of plaques not potentiating 
it. Moreover, an elevated MMP2 activity in plaques and 
a high aggregation-potentiating effect of plaques have 
been associated with a higher rate of subsequent ischemic 
cerebrovascular events [15].
Our results indicate that, there is a distinct 
methylation pattern of MMPs and TIMPs genes between 
stable and unstable carotid plaque, that might play a 
role in plaque instability. Three CpGs reached statistical 
significance, a bigger sample could have boosted the 
power of the study to identify other CpGs. While there 
is no previous literature linking our primary association, 
MMP24, with atherosclerosis, a vast catalog of studies 
on RNA expression, plasma levels studies, genetics 
and methylation [5–8, 13, 15] in the MMP gene family 
corroborate the biopathological plausibility of its role in 
plaque progression.
In summary, we characterized MMPs and TIMPs 
DNAm patterns in atheromatous plaque, which led us 
to observe significant differences between stable and 
ulcerated portions in plaque tissue for MMP24 and TIMP2. 
Differences in MMP24 were also observed in blood 
samples between atherothrombotic stroke patients and 
healthy controls. The generalized hypermethylation found 
in ulcerated portions and samples from healthy controls is 
in line with other methylation studies. Functional analysis 
of the implications of methylation levels changes in 
MMP24 and TIMP2 have in their expression levels are 
needed to link this finding with the biopathology of plaque 
destabilization. Studies with larger sample size, to confirm 
our results.
Limitations
The study presents a small sample size, which might 
have limited the ability to find other potential biomarkers. 
Although other studies have also performed epigenetic 
experiments in a limited number of atherothrombotic 
plaques [10]. Using samples from the same patient 
decreases the variability, thus increasing the statistical 
power. Moreover, our blood results corroborate that 
MMP24 may play a role in atherosclerosis due to 
epigenetic modifications. Additionally, having whole 
blood DNA samples derived from the same atheromatous 
plaque subjects would have given more insight into useful 
methylation biomarkers of plaque vulnerability.
MATERIALS AND METHODS
Human atherosclerotic plaque samples
Three atherosclerotic plaque samples were obtained 
at Hospital Universitari Mutua de Terrassa (Barcelona, 
Spain), according to a protocol approved by the local 
ethics committee. Patients with >70% stenosis underwent 
carotid endarterectomy surgery, following European 
Society for Vascular Surgery Guidelines [16]. Plaque 
sizes ranged from 1.5 to 3.5 cm and the samples were 
stored at –80°C until the analysis. Stable and ulcerated 
portions of plaque were macroscopically identified and 
sectioned prior to DNA extraction by a trained technician 
(Supplementary Figure 1). Sample selection was based on 
the size and definition of stable and ulcerated portions. 
Sample information for donor-matched plaque pairs is 
shown in Supplementary Table 1.
Human whole blood samples
Methylation levels of MMPs and TIMPs in plaque 
tissue were crossed with methylation levels in blood 
tissue in two new independent cohorts. Ischemic stroke-
cohort 1 (ISC-1): 37 atherothrombotic stroke patients 
and 6 healthy controls, from the GRECOS study [17]; 
Ischemic stroke-cohort 2 (ISC-2): 80 atherothrombotic 
patients from the BASICMAR prospective register [18] 
and 184 healthy controls from REGICOR population-
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based cohort (Supplementary Table 2). In both cases, only 
atherothrombotic stroke samples were selected as defined 
by the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) [19].
Local ethics committee approved the study (PR (AG) 
03/2007). All patients signed a written informed consent.
DNA preparation and bisulfite conversion
Genomic DNA was extracted from <10 mg of frozen 
plaque tissue using the QIAamp DNA Micro Kit (Qiagen, 
Hilden, Germany) tissue protocol. Genomic DNA, from 
fresh whole blood samples, was obtained using the 
Gentra Puregene Blood Kit (Qiagen, Hilden, Germany), 
following the manufacturer’s instructions, in the Plaque-
tissue samples and the Blood-tissue ISC-1 samples. 
Blood-tissue ISC-2 samples were extracted using manual 
salt precipitation in Banco Nacional de ADN (Instituto de 
Salud Carlos III, Madrid, Spain).
Methylation assays
Genome-wide DNAm was assessed using the Infinium 
HumanMethylation450 BeadChip (450K), in plaque and 
ISC-1 samples, and Infinium MethylationEPIC (EPIC) in 
ISC-2 samples, (Illumina Inc, San Diego, CA, USA).
CpG site selection
Annotation information provided by Illumina’s 
450K BeadChip manifest [20] was used to identify CpG 
sites (CpGs) mapped into the MMP and TIMP family of 
genes. A total of 27 genes (23 MMPs and 4 TIMPs) were 
identified, comprising a total of 464 CpGs, of which 415 
passed quality controls (Supplementary Table 6).
Data preprocessing, quality control (QC), and 
analysis
Functions from the ChAMP Bioconductor 
package v.2.9.19 [21] were used for data preprocessing, 
QC, normalization and univariate analysis. Following 
the ChAMP package pipeline recommendations, 
QC metrics were examined to determine the success 
of the bisulfite conversion and subsequent array 
hybridization. Fluorescence intensities were imported 
from GenomeStudio, then probe filtering was performed 
to remove probes that had failed to hybridize (detection 
P > 0.05) and were not represented by a minimum of 3 
beads on the array. CpG sites containing documented 
single-nucleotide polymorphisms were also excluded. 
Multidimensional scaling plots were used to evaluate sex 
outliers based on chromosome X data. Multidimensional 
scaling and principal components were also used to 
check for unknown population structures. Probes 
mapping to X chromosome were not removed, so as 
not to rule out TIMP1 CpG sites, mapped in the X 
chromosome. Recommended BMIQ method was used 
for data normalization. We also adjusted our data by cell 
proportion, with champ. refbase function.
Finally, Wilcoxon rank-sum test and the Champ. 
DMP function were used to identify differentially 
methylated positions among groups in the univariate 
model (Model_1), and glm for the multivariate models. 
Multivariate model, Model_2, included sex, age, 
smoking, variables, and Model_3 included sex, smoking, 
hypertension (HTA) and dyslipidemia (DL). This pipeline 
was used for the three cohorts, atherosclerotic plaque, 
ISC-1, and ISC-2, (except: ISC-2 cohort did remove the 
CpG sites mapped in the X chromosome).
Statistical analysis and power calculation
The significance threshold, for all statistical tests, 
was set at False Discovery Rate (FDR) p < 0.05. Statistical 
analyses were performed using Bioconductor packages 
(http://www.bioconductor.org) and R software (http://
www.cran.r-project.org).
As described by Tsai P et al., [22] we have an 80% 
power to detect p < 0.05, considering Cohen’s d effect size 
between 1.93–3.33 in the paired-plaque sample study and 
over 95% to detect p < 0.05, considering Cohen’s d effect 
size between 1.47–1.80.
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